An Atlanta Journal-Constitution investigation published October 17, 2026 found that more than a dozen Georgia med spas and wellness clinics, along with certain pharmacies, are openly marketing and selling retatrutide — an investigational peptide not approved by the FDA — directly to patients.
Retatrutide, currently in development by Eli Lilly, is being offered alongside FDA-approved GLP-1 drugs such as semaglutide and tirzepatide, subject only to a provider’s approval. The FDA has stated that retatrutide cannot lawfully be used in compounding under federal law.
The investigation reveals a live supply chain for an unapproved investigational drug moving through telemedicine and pharmacy channels, despite the FDA’s explicit position and Eli Lilly’s active enforcement campaign against knockoff sellers.
What happened
According to the AJC report, Georgia weight-loss clinics and telehealth providers are advertising retatrutide to patients as part of their treatment offerings. Patients can obtain the drug through online consultations and provider approval, with the unapproved peptide listed alongside legally marketed GLP-1 medications.
Eli Lilly, which is developing retatrutide, has filed multiple lawsuits and referred over 200 entities to regulators in an attempt to halt sales of unauthorized versions. The company has also alerted regulators to the ongoing distribution.
The FDA has taken the position that retatrutide does not meet the legal criteria for compounding, meaning pharmacies that prepare and dispense the drug may be operating outside federal law.
Why it matters
The open sale of an investigational, unapproved drug through pharmacy and telehealth channels raises significant patient safety concerns. Retatrutide has not completed the FDA’s review process, meaning its safety and efficacy profile has not been independently evaluated for the general public.
The situation also creates immediate legal risk for the pharmacies, clinics, and telehealth companies involved. With the FDA stating that retatrutide cannot be compounded and Eli Lilly pursuing litigation, entities selling the drug may face regulatory action, civil liability, or both.
For the broader compounding and telehealth industries, the case underscores the tension between demand for next-generation weight-loss treatments and the regulatory boundaries that govern what pharmacies can legally prepare and dispense.
What to watch next
- Whether the FDA takes direct enforcement action against the Georgia pharmacies and clinics identified in the AJC investigation.
- The trajectory of Eli Lilly’s lawsuits against sellers of unauthorized retatrutide and whether additional defendants are named.
- Whether other states see similar patterns of retatrutide sales through telehealth and compounding channels.
- The clinical development timeline for retatrutide and any future FDA decisions on its approval status.
Sources
Industry information only. Not medical or legal advice.
